PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy

Advances in Biological Regulation

Volumn 52, Issue 1, 2012, Pages 214-227

  Martelli, Alberto M ^a   Tabellini, Giovanna ^b   Ricci, Francesca ^c   Evangelisti, Camilla ^a   Chiarini, Francesca ^a   Bortul, Roberta ^d   McCubrey, James A ^e   Manzoli, Francesco Antonio ^f  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

^e EAST CAROLINA UNIVERSITY   (United States)

^f RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865634004     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2011.09.019     Document Type: Article

References (77)

1. Albert S., Serova M., Dreyer C., Sablin M.P., Faivre S., Raymond E. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs 2010, 19:919-930.
2. Barata J.T., Cardoso A.A., Nadler L.M., Boussiotis V.A. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood 2001, 98:1524-1531.
3. Barata J.T., Boussiotis V.A., Yunes J.A., Ferrando A.A., Moreau L.A., Veiga J.P., et al. IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. Blood 2004, 103:1891-1900.
4. Barata J.T., Keenan T.D., Silva A., Nadler L.M., Boussiotis V.A., Cardoso A.A. Common γ chain-signaling cytokines promote proliferation of T-cell acute lymphoblastic leukemia. Haematologica 2004, 89:1459-1467.
5. Barata J.T., Silva A., Brandao J.G., Nadler L.M., Cardoso A.A., et al. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med 2004, 200:659-669.
6. Batista A., Barata J.T., Raderschall E., Sallan S.E., Carlesso N., Nadler L.M., et al. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol 2011, 39:457-472.
7. Blagden S.P., Willis A.E. The biological and therapeutic relevance of mRNA translation in cancer. Nat Rev Clin Oncol 2011, 8:280-291.
8. Brachmann S.M., Hofmann I., Schnell C., Fritsch C., Wee S., Lane H., et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A 2009, 106:22299-22304.
9. Chapuis N., Tamburini J., Green A.S., Vignon C., Bardet V., Neyret A., et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 2010, 16:5424-5435.
10. Chen J., Petrus M., Bryant B.R., Phuc Nguyen V., Stamer M., Goldman C.K., et al. Induction of the IL-9 gene by HTLV-I tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood 2008, 111:5163-5172.
11. Chiarini F., Del Sole M., Mongiorgi S., Gaboardi G.C., Cappellini A., Mantovani I., et al. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 2008, 22:1106-1116.
12. Chiarini F., Falà F., Tazzari P.L., Ricci F., Astolfi A., Pession A., et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 2009, 69:3520-3528.
13. Chiarini F., Grimaldi C., Ricci F., Tazzari P.L., Evangelisti C., Ognibene A., et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010, 70:8097-8107.
14. Clappier E., Collette S., Grardel N., Girard S., Suarez L., Brunie G., et al. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia 2010, 24:2023-2031.
15. Cox C.V., Martin H.M., Kearns P.R., Virgo P., Evely R.S., Blair A. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood 2007, 109:674-682.
16. Demoulin J.B., Louahed J., Dumoutier L., Stevens M., Renauld J.C. MAP kinase activation by interleukin-9 in lymphoid and mast cell lines. Oncogene 2003, 22:1763-1770.
17. Di Nicolantonio F., Arena S., Tabernero J., Grosso S., Molinari F., Macarulla T., et al. J Clin Invest 2010, 120:2858-2866.
18. Elkholi R., Floros K.V., Chipuk J.E. The role of BH3-only proteins in tumor cell development, signaling, and treatment. Genes Cancer 2011, 2:523-537.
19. Evangelisti C., Ricci F., Tazzari P., Tabellini G., Battistelli M., Falcieri E., et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011, 25:781-791.
20. Feldman M.E., Apsel B., Uotila A., Loewith R., Knight Z.A., Ruggero D., et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009, 7:e38.
21. Goldberg J.M., Silverman L.B., Levy D.E., Dalton V.K., Gelber R.D., Lehmann L., et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003, 21:3616-3622.
22. Green A.S., Chapuis N., Lacombe C., Mayeux P., Bouscary D., Tamburini J. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle 2011, 10:2115-2120.
23. Green A.S., Chapuis N., Maciel T.T., Willems L., Lambert M., Arnoult C., et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 2010, 116:4262-4273.
24. Gregorj C., Ricciardi M.R., Petrucci M.T., Scerpa M.C., De Cave F., Fazi P., et al. ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2007, 109:5473-5476.
25. Guo W., Schubbert S., Chen J.Y., Valamehr B., Mosessian S., Shi H., et al. Suppression of leukemia development caused by PTEN loss. Proc Natl Acad Sci U S A 2011, 108:1409-1414.
26. Johnson S.E., Shah N., Bajer A.A., LeBien T.W. IL-7 activates the phosphatidylinositol 3-kinase/AKT pathway in normal human thymocytes but not normal human B cell precursors. J Immunol 2008, 180:8109-8117.
27. Johnson S.E., Shah N., Panoskaltsis-Mortari A., LeBien T.W. Murine and human IL-7 activate STAT5 and induce proliferation of normal human pro-B cells. J Immunol 2005, 175:7325-7331.
28. Jotta P.Y., Ganazza M.A., Silva A., Viana M.B., da Silva M.J., Zambaldi L.J., et al. Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 2010, 24:239-242.
29. Kharas M.G., Okabe R., Ganis J.J., Gozo M., Khandan T., Paktinat M., et al. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood 2010, 115:1406-1415.
30. Kindler T., Cornejo M.G., Scholl C., Liu J., Leeman D.S., Haydu J.E., et al. K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to γ-secretase inhibitors. Blood 2008, 112:3373-3382.
31. Konopleva M., Andreeff M. Targeting the leukemia microenvironment. Curr Drug Targets 2007, 8:685-701.
32. Konopleva M., Konoplev S., Hu W., Zaritskey A.Y., Afanasiev B.V., Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002, 16:1713-1724.
33. Konopleva M., Tabe Y., Zeng Z., Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat 2009, 12:103-113.
34. Konopleva M.Y., Jordan C.T. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011, 29:591-599.
35. Kox C., Zimmermann M., Stanulla M., Leible S., Schrappe M., Ludwig W.D., et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 2010, 24:2005-2013.
36. Lee G., Origanti S., White L.S., Sun J., Stappenbeck T.S., Piwnica-Worms H. Contributions made by CDC25 phosphatases to proliferation of intestinal epithelial stem and progenitor cells. PLoS One 2011, 6:e15561.
37. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008, 7:1851-1863.
38. Martelli A.M., Evangelisti C., Chappell W., Abrams S.L., Basecke J., Stivala F., et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011, 25:1064-1079.
39. Martelli A.M., Papa V., Tazzari P.L., Ricci F., Evangelisti C., Chiarini F., et al. Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. Leukemia 2010, 24:687-698.
40. Misaghian N., Ligresti G., Steelman L.S., Bertrand F.E., Basecke J., Libra M., et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009, 23:25-42.
41. Nakao M., Janssen J.W., Seriu T., Bartram C.R. Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology. Leukemia 2000, 14:312-315.
42. Nishimura M., Kakinuma S., Yamamoto D., Kobayashi Y., Suzuki G., Sado T., et al. Elevated interleukin-9 receptor expression and response to interleukins-9 and -7 in thymocytes during radiation-induced T-cell lymphomagenesis in B6C3F1 mice. J Cell Physiol 2004, 198:82-90.
43. Papa V., Tazzari P.L., Chiarini F., Cappellini A., Ricci F., Billi A.M., et al. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008, 22:147-160.
44. Parsyan A., Svitkin Y., Shahbazian D., Gkogkas C., Lasko P., Merrick W.C., et al. mRNA helicases: the tacticians of translational control. Nat Rev Mol Cell Biol 2011, 12:235-245.
45. Pearce L.R., Komander D., Alessi D.R. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 2010, 11:9-22.
46. + CML stem/progenitor cells. Leukemia 2011, 25:1159-1167.
47. Pestova T.V., Kolupaeva V.G. The roles of individual eukaryotic translation initiation factors in ribosomal scanning and initiation codon selection. Genes Dev 2002, 16:2906-2922.
48. Petroulakis E., Mamane Y., Le Bacquer O., Shahbazian D., Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 2006, 94:195-199.
49. Pillozzi S., Masselli M., De Lorenzo E., Accordi B., Cilia E., Crociani O., et al. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood 2011, 117:902-914.
50. Pui C.H., Robison L.L., Look A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371:1030-1043.
51. Renauld J.C., Kermouni A., Vink A., Louahed J., Van Snick J. Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell oncogenesis. J Leukoc Biol 1995, 57:353-360.
52. Renauld J.C., Vink A., Louahed J., Van Snick J. Interleukin-9 is a major anti-apoptotic factor for thymic lymphomas. Blood 1995, 85:1300-1305.
53. Renneville A., Kaltenbach S., Clappier E., Collette S., Micol J.B., Nelken B., et al. Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies. Leukemia 2010, 24:476-480.
54. Ruggero D., Montanaro L., Ma L., Xu W., Londei P., Cordon-Cardo C., et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004, 10:484-486.
55. Scupoli M.T., Donadelli M., Cioffi F., Rossi M., Perbellini O., Malpeli G., et al. Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-κB and JNK/AP-1 pathways. Haematologica 2008, 93:524-532.
56. Scupoli M.T., Perbellini O., Krampera M., Vinante F., Cioffi F., Pizzolo G. Interleukin 7 requirement for survival of T-cell acute lymphoblastic leukemia and human thymocytes on bone marrow stroma. Haematologica 2007, 92:264-266.
57. Scupoli M.T., Vinante F., Krampera M., Vincenzi C., Nadali G., Zampieri F., et al. Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7. Haematologica 2003, 88:1229-1237.
58. Shahbazian D., Parsyan A., Petroulakis E., Hershey J., Sonenberg N. eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. Cell Cycle 2010, 9:4106-4109.
59. Shahbazian D., Parsyan A., Petroulakis E., Topisirovic I., Martineau Y., Gibbs B.F., et al. Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol Cell Biol 2010, 30:1478-1485.
60. Shahbazian D., Roux P.P., Mieulet V., Cohen M.S., Raught B., Taunton J., et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 2006, 25:2781-2791.
61. Silva A., Laranjeira A.B., Martins L.R., Cardoso B.A., Demengeot J., Yunes J.A., et al. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res 2011, 71:4780-4789.
62. Silva A., Yunes J.A., Cardoso B.A., Martins L.R., Jotta P.Y., Abecasis M., et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008, 118:3762-3774.
63. Steelman L.S., Franklin R.A., Abrams S.L., Chappell W., Kempf C.R., Basecke J., et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011, 25:1080-1094.
64. Sunayama J., Matsuda K., Sato A., Tachibana K., Suzuki K., Narita Y., et al. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 2010, 28:1930-1939.
65. Swainson L., Kinet S., Mongellaz C., Sourisseau M., Henriques T., Taylor N. IL-7-induced proliferation of recent thymic emigrants requires activation of the PI3K pathway. Blood 2007, 109:1034-1042.
66. Taguchi T., Takenouchi H., Shiozawa Y., Matsui J., Kitamura N., Miyagawa Y., et al. Interleukin-7 contributes to human pro-B-cell development in a mouse stromal cell-dependent culture system. Exp Hematol 2007, 35:1398-1407.
67. Tamburini J., Green A.S., Bardet V., Chapuis N., Park S., Willems L., et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009, 114:1618-1627.
68. Tamburini J., Green A.S., Chapuis N., Bardet V., Lacombe C., Mayeux P., et al. Targeting translation in acute myeloid leukemia: a new paradigm for therapy?. Cell Cycle 2009, 8:3893-3899.
69. Tazzari P.L., Cappellini A., Ricci F., Evangelisti C., Papa V., Grafone T., et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007, 21:427-438.
70. Tazzari P.L., Tabellini G., Bortul R., Papa V., Evangelisti C., Grafone T., et al. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 2007, 21:886-896.
71. van Gorp A.G., van der Vos K.E., Brenkman A.B., Bremer A., van den Broek N., Zwartkruis F., et al. AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B. Oncogene 2009, 28:95-106.
72. Xiao H., Yin T., Wang X.Y., Uchida T., Chung J., White M.F., et al. Specificity of interleukin-2 receptor γ chain superfamily cytokines is mediated by insulin receptor substrate-dependent pathway. J Biol Chem 2002, 277:8091-8098.
73. Yu L., Slovak M.L., Mannoor K., Chen C., Hunger S.P., Carroll A.J., et al. Microarray detection of multiple recurring submicroscopic chromosomal aberrations in pediatric T-cell acute lymphoblastic leukemia. Leukemia 2011, 25:1042-1046.
74. Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M, et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 2011;43:932-9.
75. Zhao W.L. Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia 2010, 24:13-21.
76. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011, 12:21-35.
77. Zuurbier L., Homminga I., Calvert V., te Winkel M.L., Buijs-Gladdines J.G., Kooi C., et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia 2010, 24:2014-2022.